BioSpace News Archive

Medline announced it has entered a multi-year prime vendor partnership with Florida-based Synthase Collaborative, a partnership of four post-acute and home-based care organizations that provide not-for-profit hospice, palliative care, and other chronic Illness management community focused programs and services.

Maternova, Inc., accelerating advances in maternal and infant health through innovative, accessible solutions, and MedMira Inc. (TSXV: MIR), a developer and manufacturer of rapid diagnostics, today announced that the companies have entered into a multinational distribution agreement.

This tumor analysis study was a collaborative effort between MediciNova, Dr. Patrick Wen, and Dr. Lathia.

AscletisPharma Inc. (HKEX: 1672, “Ascletis”) today presented positive data from Phase I clinical trial of ASC10, a broad-spectrum antiviral double prodrug, at Conference on Retroviruses and Opportunistic Infections (CROI) 2023 in Seattle, the U.S.

Azafaros B.V. today announced its progress in ongoing interactions with Health Authorities regarding its lead asset, AZ-3102.

Medivir AB announced that the initial dose escalation part of the company’s 1b/2a study with the candidate drug fostroxacitabine bralpamide in hepatocellular carcinoma, in combination with Lenvima®, was successfully completed.

Regenative Labs (Regenative), a leading HCT/P manufacturer, announces updates to its 2022 MDPI retrospective study on tissue defects in and around the knee.

Henry Schein, Inc. announced its presence at the 2023 Chicago Dental Society Midwinter meeting, featuring a comprehensive display of the Company’s expansive portfolio of products and solutions, designed to help oral health professionals enhance every aspect of their practice efficiency and the patient experience.

Oxford Biomedica, a leading gene and cell therapy group, announces that Dr Frank Mathias will officially join Oxford Biomedica as Chief Executive Officer and Board member on Monday, 27th March 2023.

Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX), today announced the upcoming presentation of new analyses of results from the SOLOIST-WHF Phase 3 outcomes study of its investigational sotagliflozin product at the American College of Cardiology’s 72nd Annual Scientific Session Together With World Heart Federation’s World Congress of Cardiology in New Orleans, Louisiana.